VEMINSYN secured investment from L'Oréal Group in 2025.

L'Oréal Group has announced an investment in VEMINSYN, while entering into a strategic partnership with VEMINSYN.

Pioneer of Customized Collagen in China| VEMINSYN, together with its subsidiary Suzhou Shiguang Pharmaceutical, makes its debut at the grand AMWC event.

From October 18 to 20, VEMINSYN, together with its subsidiary Suzhou Shiguang Pharmaceutical Biotechnology Co., Ltd., was invited to participate in AMWC China 2024 World Congress on Aesthetic Medicine and Anti-Aging held in Chengdu.

Leading the Industry | First Group Standard for In Vivo Transdermal Permeation Testing on Human Skin Officially Released

On September 10, 2024, the group standard Transdermal Permeation Test of Cosmetic Ingredients – In Vivo Raman Spectroscopy on Human Body (T/SHRH 064-2024), formulated under the leadership of VEMINSYN as the lead organization, was officially promulgated.

Sustained Momentum in R&D & Innovation | VEMINSYN Successfully Registers New Ingredient with PCPC and Secures Patent for Type XVII Collagen Peptide

Type XVII Collagen Peptide, independently developed and produced by the R&D team of VEMINSYN, has been successfully registered with an INCI name and granted an invention patent

The Power of Plant Callus Culture | VEMINSYN Donates 30 Rare Cloned Seedlings of Bletilla sinensis to the National Orchid Conservation Center

On August 7, 2024, Dr. Jiayue Chen, Co-founder of VEMINSYN, together with Dr. Zhou Yu, was invited to visit the National Orchid Conservation Center and attend a public welfare seminar focused on the conservation of Bletilla sinensis, an endangered plant species.

Bioactive Materials Innovation Platform——VEMINSYN Completes Nearly RMB 100 Million Series A Financing, Led by CITIC Capital.

As an emerging innovator in the field of biomanufacturing, VEMINSYN, a pioneering platform for novel bioactive materials, has recently announced the completion of its Series A financing round of nearly RMB 100 million.